BofA warns Fed risks policy mistake with early rate cuts
LOS ANGELES - Immix Biopharma, Inc. (NASDAQ:IMMX), a clinical-stage biopharmaceutical company with a market capitalization of $79.38 million, announced Wednesday that it plans to seek external partnerships for its NXC-201 CAR-T cell therapy programs targeting diseases beyond its lead indication of relapsed/refractory AL Amyloidosis. The company’s stock has shown strong momentum, gaining over 41% in the past six months according to InvestingPro data.
The clinical-stage biopharmaceutical company said it is currently dosing patients with its BCMA-targeted chimeric antigen receptor T cell therapy in several other serious diseases. While maintaining focus on completing its NEXICART-2 trial for AL Amyloidosis, the company intends to license out these additional disease programs to partners. InvestingPro analysis shows the company maintains a strong balance sheet with more cash than debt, though it’s currently experiencing rapid cash burn - a common characteristic among clinical-stage biotech companies.
"While we are singularly focused on completing NEXICART-2 in relapsed/refractory AL Amyloidosis for BLA submission, promising NXC-201 clinical results could offer extraordinary one-and-done solutions in a number of other serious diseases," said Ilya Rachman, CEO of Immix Biopharma.
The company’s Chief Financial Officer, Gabriel Morris, indicated that such partnerships could help fund the path to Biologics License Application submission for FDA approval of NXC-201.
NXC-201 is described as a sterically-optimized BCMA-targeted CAR-T cell therapy with a digital filter that filters out non-specific activation. The therapy has received Regenerative Medicine Advanced Therapy designation from the FDA and Orphan Drug Designation in both the US and EU.
The company plans to present forthcoming clinical data at upcoming scientific forums, according to the press release statement.
Interim results from the NEXICART-2 study were previously presented at ASCO 2025 by Dr. Heather Landau of Memorial Sloan Kettering Cancer Center.
In other recent news, Immix Biopharma, Inc. reported that its NXC-201 therapy has shown a favorable safety profile with no neurotoxicity observed in patients with low-volume disease. The company is advancing its NEXICART-2 clinical trial for relapsed/refractory AL amyloidosis and plans to submit a Biologics License Application to the FDA. Immix Biopharma has expanded the NEXICART-2 trial to 18 sites across the United States, aiming to increase patient access to this therapy. H.C. Wainwright reiterated its Buy rating for Immix Biopharma, maintaining a price target of $7.00, highlighting the accelerated progress in the trial. Interim results from the trial presented at the ASCO meeting showed a 100% response rate among participants, with 70% achieving a hematologic complete response. Additionally, Immix Biopharma has entered into an At The Market Offering Agreement with Citizens JMP Securities, LLC, allowing the company to offer and sell shares of its common stock. This agreement is conducted under the company’s existing Registration Statement on Form S-3.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.